The European Medicines Agency EMA has announced a special meeting for September 1. Then approval applications for booster vaccinations against the ommicron variant of the virus should be discussed. Both Moderna and its Biontech partner Pfizer want to market such vaccines.
The UK was the first country to approve a vaccine in mid-month that is effective against both the mother coronavirus and the ommicron variant. The vaccine from the American manufacturer Moderna can be used as a booster for adults, the British health authority MHRA announced. The decision was based on clinical studies that had shown a “strong immune response.” In the EU, Omicron vaccines from both Moderna and Biontech/Pfizer are still being tested.
The Moderna vaccine, called Spikevax bivalent Original/Omicron, targets both the original strain of the coronavirus, which first appeared in 2020, and the omicron variant BA.1. “Good” results were also achieved for the subtypes BA.4 and BA.5 of the omicron variant, the MHRA announced.
The modified Moderna vaccine is also currently under investigation by the EU medicines agency EMA. At the same time, the EMA is investigating a modified corona vaccine from Biontech/Pfizer, whose approval is planned for the autumn.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
